Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 25, 2010

Stemina Taps Agilent Tools for Stem Cell Metabolite Biomarker Discovery

  • Stemina Biomarker Discovery will use Agilent Technologies’ tools to accelerate its metabolomic research. The firm is leveraging metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.

    Agilent is providing a 1290 Infinity UHPLC system to separate stem cell metabolites along with a 6530 Accurate-Mass quadrupole time-of-flight mass spectrometer to identify those metabolites. Agilent is also providing Mass Profiler Professional software to help Stemina researchers interpret data generated by the metabolomics experiments.

    “We have used Agilent technology since Stemina began operations in 2007 and have been very pleased with the instrumentation, support, and collaboration we have experienced with Agilent,” remarks Beth Donley, Stemina CEO.

    Stemina’s cell-based assays arise from the convergence of human embryonic stem cells (hESCs) and metabolomics. The company uses Agilent mass spectrometry systems to analyze small molecules secreted by hESCs and differentiated cells such as heart and neural cells made from hESCs in response to drugs, injury, or disease. The company’s devTox™ assay is used to screen pharmaceutical agents for teratogenicity.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »